IP Library Patent Application 14356064
Patent Application
App. No. 14/356,064

DRUG SCREENING AND POTENCY ASSAYS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/356,064
Abstract

The present invention concerns bioactive renal cell populations, in particular a B2 cell population comprising an enriched population of tubular cells and wherein the renal cell population is depleted of a B1 cell population, renal cell constructs, and methods of screening test agents using the bioactive renal cell populations.

Claims (29)

1 . A method of determining a level of renal toxicity of a test agent comprising

a) culturing a plurality of concentrations of a test agent with a heterogeneous renal cell population comprising a B2 cell population comprising an enriched population of tubular cells, and wherein the heterogeneous renal cell population is depleted of a B1 cell population; and

b) determining a level of toxicity of said test agent, wherein the presence of at least one toxicity indicator is indicative of the level of renal toxicity of said test agent.

2 . The method of claim 1 , wherein the heterogeneous renal cell population further comprises a B4 cell population comprising one or more of erythropoietin (EPO)-producing cells, glomerular cells and vascular cells.

3 . The method of claim 2 , wherein the heterogeneous renal cell population further comprises a B3 cell population.

4 . The method of claim 3 , wherein the heterogeneous renal cell population further comprises a B5 cell population.

5 . The method of claim 1 , wherein the cell population is cultured as spheroids.

6 . The method of claim 1 , wherein the heterogeneous renal cell population is cultured on a matrix.

7 . The method of claim 6 , wherein the matrix is a three-dimensional (3-D) matrix.

8 . The method of claim 1 , wherein the toxicity indicator is decreased GGT expression.

9 . The method of claim 1 , wherein the toxicity indicator is a change Aquaporin-1 expression relative to control.

10 . The method of claim 1 , wherein the toxicity indicator is a change in Aquaporin-2 expression relative to control.

11 . The method of claim 1 , wherein the toxicity indicator is LDH.

12 . The method of claim 1 , wherein the toxicity indicator is a change in phenotype of the cell population relative to control.

13 . The method of claim 1 , wherein the determination of the level of renal toxicity of the test agent comprises calculating a TC50 for the test agent.

14 . A method for determining metabolism of a test agent comprising

a) incubating a test agent and an enzyme with a heterogeneous renal cell population comprising a B2 cell population comprising an enriched population of tubular cells, and wherein the heterogeneous renal cell population is depleted of a B1 cell population; and

b) detecting one or more metabolites of the test agent.

15 . An in vitro method for identifying a test agent suitable for therapeutic use in a human subject having a kidney disorder comprising

a) contacting a test agent with a heterogeneous renal cell population comprising a B2 cell population that is characterized by a phenotype selected from the group consisting of expression of a proliferative marker and an M2 phenotype, wherein the B2 cell population comprises an enriched population of tubular cells; and

b) determining whether the test agent modulates the expression of a proliferative marker and/or an M2 phenotype of the heterogeneous renal cell population relative to a non-contacted control cell population.

16 . The method of claim 15 , wherein the heterogeneous renal cell population further comprises a B4 cell population comprising one or more of erythropoietin (EPO)-producing cells, glomerular cells and vascular cells.

17 . The method of claim 15 , wherein the heterogeneous renal cell population is cultured on a matrix.

18 . The method of claim 17 , wherein the matrix is a three-dimensional (3-D) matrix.

19 . An organoid comprising a heterogeneous renal cell population comprising a B2 cell population comprising an enriched population of tubular cells, and wherein the heterogeneous renal cell population is depleted of a B1 cell population.

20 . A method of forming an organoid comprising a heterogeneous renal cell population comprising a B2 cell population comprising an enriched population of tubular cells, and wherein the heterogeneous renal cell population is depleted of a B1 cell population, comprising culturing the heterogenerous renal cell population in a culture system selected from the group consisting of i) 2D culture; ii) 3D culture: COL(I) gel; iii) 3D culture: Matrigel; iv) 3D culture: spinners, followed by COL(I)/Matrigel; and v) 3D culture: COL(IV) gel.

21 . A method of determining a regenerative potential of a heterogeneous cell population comprising a B2 cell population comprising an enriched population of tubular cells, and wherein the heterogeneous renal cell population is depleted of a B1 cell population, comprising

a) culturing the heterogeneous renal cell population; and

b) determining the regenerative potential of the heterogeneous cell population, wherein the formation of tubules and/or organoids is indicative of a regenerative potential.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Aug 2, 2016
From: REGENMEDTX, LLC; REGENMED (CAYMAN) LTD.
To: REGENMED (CAYMAN) LTD.
Reel/Frame 039550/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2015
From: BRUCE, ANDREW T; KELLEY, RUSSELL W; BERTRAM, TIMOTHY A; CHOUDHURY, SUMANA
To: TENGION, INC.
Reel/Frame 037018/0289 →
CHANGE OF OWNERSHIP Recorded Nov 11, 2015
From: TENGION, INC.
To: REGENMEDTX, LLC
Reel/Frame 037098/0627 →